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Abstract Hypoxia activates the transcription factor, hypoxia
inducible factor-1 (HIF-1). Besides hypoxia, HIF-1 can be ac-
tivated under normoxic conditions by nitric oxide. The signal
transduction pathways involved in HIF-1K stabilization, HIF-1
DNA binding and transactivation by NO and hypoxia in micro-
vascular endothelium remains unknown. We report that protein
phosphorylation is involved in HIF-1 activation during hypoxia
and NO. The phosphatidylinositol 3-kinase (PI-3K)/Akt path-
way has di¡erential e¡ects on HIF-1 activation by hypoxia and
NO. Our data indicate that the PI-3K/Akt pathway is insu⁄-
cient for HIF-1K induction by hypoxia. The lipid and protein
phosphatase activities of PTEN also appear to be involved in
regulation of HIF-1K by NO.
0 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Mammalian cells adapt to situations of reduced oxygen
availability (hypoxia) by altering glucose metabolism, angio-
genesis, vasodilation and erythropoiesis [1]. This is achieved
by regulating proteins such as erythropoietin, vascular endo-
thelial growth factor, glycolytic enzymes and nitric oxide syn-
thase. These proteins are under control of the transcription
factor hypoxia inducible factor-1 (HIF-1). Functional HIF-1
is a heterodimeric unit composed of a HIF-1K and a HIF-1L
subunit. The HIF-1 subunits are constitutively transcribed
and translated, but HIF-1K protein levels are regulated by
ubiquitination and proteosomal degradation [2,3]. Under nor-
moxic conditions, HIF-1K is a cytosolic protein with a short
half-life. During hypoxia, HIF-1K degradation is progressively
inhibited. Stabilized HIF-1K translocates to the nucleus, di-
merizes with HIF-1L and regulates gene transcription by bind-
ing to hypoxia response elements on genes [4]. The mecha-
nisms of HIF-1K modi¢cation and destruction, including the
involvement of prolyl hydroxylases, E3 ubiquiting ligase and
von Hippel^Lindau tumor suppressor protein, have recently
been determined [5^8]. In addition to prolyl hydroxylation,
control of hypoxia-induced HIF-1K levels involves regulatory
pathways such as ROS [9], MAPK cascades [10^12], diacyl-
glycerol kinase [13], and PI-3K (phosphatidylinositol-3 kinase)
[14,15].
Besides hypoxia, HIF-1 can be activated under normoxic
conditions by compounds that chelate iron such as desferrox-
amine and transition metals. Certain cytokines, growth factors
and hormones have also been shown to activate HIF-1 under
normoxic conditions [15^17]. Recently, we and others have
shown that chemically diverse nitric oxide (NO) donors and
endogenous NO evoke HIF-1K stabilization, HIF-1 DNA
binding and downstream target gene expression under nor-
moxic conditions [18^21]. However, little information exists
on signal transduction pathways involved in this NO-medi-
ated response. In LLC-PKi proximal tubular cells, Sandau
et al. [22] initially noticed that the general kinase inhibitor,
genistein, and the PI-3K inhibitors, wortmannin and
LY294002, blocked HIF-1K accumulation upon exposure to
NO. They concluded that NO-evoked HIF-1 induction oc-
curred in a PI-3K-dependent manner that closely correlated
with Akt phosphorylation. Further MAPK pathways played
no role in this induction. More recently, Sandau et al. [18]
showed that HIF-1K stabilization was blocked by interrupting
the PI-3K/Akt pathway following exposure to both hypoxia
and NO. In contradistinction, by using a variety of di¡erent
cell types, Arsham et al. [23] showed that inhibitors of the PI-
K/Akt pathway did not block the hypoxic induction of HIF-
1K. Alvarez-Tejado et al. [24] also demonstrated that PI-3K/
Akt activity is not su⁄cient for HIF induction, nor is it es-
sential for its regulation by hypoxia. Thus it appears that
although the mechanisms involved in HIF-1K degradation
are becoming increasingly clear, the signaling pathways, espe-
cially the PI-3K/Akt pathway, that determines HIF-1K stabi-
lization, nuclear translocation and HIF-1 transactivational
ability under hypoxic or normoxic conditions, remain confus-
ing and controversial.
PI-3K catalyzes the conversion of phosphatidylinositol-4-
phosphate and phosphatidylinositol-4,5-biphosphate to phos-
phatidylinositol-3,4-biphosphate and phosphatidylinositol-
3,4,5-triphosphate. These products activate phosphatidylinosi-
tol-dependent kinase 1 (PDK1), which then phosphorylates
and activates the proto-oncogenic serine/threonine kinase
Akt (protein kinase B). Akt has downstream pro-growth,
anti-apoptotic e¡ects when activated by growth factors
through PI-3K (reviewed in [25]). This pathway is reversed
by PTEN (phosphatase and tensin homolog deleted on chro-
mosome 10), a tumor suppressor gene that encodes a dual-
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speci¢city phosphatase that can dephosphorylate tyrosine-
containing peptides, Shc, focal adhesion kinase and phospho-
inositide substrates [26^28]. While several lines of evidence
indicate that the lipid phosphatase activity of PTEN is re-
quired for tumor suppression [29,30], the physiological roles
of its protein phosphatase activity regarding suppression of
the PI-3K/Akt signaling pathway remain unclear.
In this study, we examined the signaling mechanisms in-
volved in HIF-1K stabilization, nuclear translocation and
HIF-1 transactivational ability after exposure of human mi-
crovascular endothelial cells (HMEC-1) to NO. We compared
our results to hypoxic exposure of HMEC-1. We show that
HIF-1 is activated in HMEC-1 under normoxic conditions by
NO. Protein phosphorylation events are involved in HIF-1
activation during hypoxia and NO exposure. Interestingly,
the PI-3K pathway has di¡erential e¡ects on HIF-1 activation
by hypoxia and NO. Our data indicate that the PI-3K/Akt
pathway is insu⁄cient for HIF-1K induction by hypoxia. In
addition, both the lipid phosphatase and protein phosphatase
activities of PTEN appear to be involved in regulation of
HIF-1K by NO.
2. Materials and methods
2.1. Endothelial cell culture
The HMEC-1 cell line utilized for this study was obtained from the
Centers for Disease Control and Prevention (CDC), Atlanta, GA,
USA. The cell line was immortalized by Dr. Edwin Ades, Mr. Fran-
sisco J. Candal of the CDC and Dr. Thomas Lawly of Emory Uni-
versity and was designated HMEC-1. HMEC-1 cells were cultured as
previously described [31].
2.2. Establishing hypoxic environments
Hypoxic conditions (3% O2) were generated as previously described
[31]. Viability of HMEC-1 subjected to hypoxia was also assessed as
described previously [31] using a two-color £uorescence (LIVE/
DEAD0, Molecular Probes) assay.
2.3. Plasmids
Plasmids used for transient transfections were hypoxia response
element luciferase reporter vector pEpo3PGlut1-Luc (designated
pHRE-luc), which contains a trimer of murine Epo 3P enhancer and
the Glut-1 promoter [32] (kind gift of Dr. Paul Schumaker), the ex-
pression plasmids encoding wild-type PTEN (pcDNA3-PTENwt) [33],
mutant PTEN de¢cient in lipid phosphatase activity, pcDNA3-
PTEN(G129E) [34] and mutant PTEN de¢cient in both lipid and
protein phosphates activities, pcDNA3-PTEN(C124S) [35] (kind gifts
of Dr. Marty W. Mayo), and pHRL-null (Promega), which contains a
synthetic Renilla gene sequence (hRluc) cleared of transcription factor
binding sites, thus enabling accurate control for transfection e⁄ciency
and indexing of luciferase activity.
2.4. Western blot analysis
Nuclear extracts (20 Wg) and whole cell extracts (50 Wg) were pre-
pared at the indicated times as described previously [36], resolved by
sodium dodecyl sulfate polyacrylamide gel electrophoresis (4^20%)
and electrophoretically transferred to polyvinylidene £uoride mem-
branes (PVDF, 0.45 Wm pore size). Immunodetection was performed
using HIF-1K (Santa Cruz Biotechnology), phospho-Akt (ser473) and
Akt (Cell Signaling Technology) antibodies and the Renaissance0
Western Blot Chemiluminescence Reagent Plus (Perkin Elmer Life
Sciences). All membranes were stained with Ponceau S solution
(0.2% wt/vol in 1% acetic acid; Sigma) to ensure equal loading and
transfer of proteins [37].
2.5. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared at the indicated times and 10 Wg
used for EMSA with a consensus HIF-1 oligonucleotide (Santa Cruz
Biotechnology) as described previously [31]. Speci¢c HIF-1K binding
was previously demonstrated by a competitive EMSA with 100-fold
excess unlabeled double-stranded HIF-1 oligonucleotide in the bind-
ing reaction prior to the addition of the end-labeled oligonucleotide
and by super-shift assays using a primary HIF-1K antibody [21].
Densitometry of the shifted bands was performed using Kodak Dig-
ital Sciences EDAS 120 system, with 1D Image analysis software, and
results obtained were expressed as relative densitometric units.
2.6. Transient transfections and dual luciferase reporter assay
HMEC-1 cells were co-transfected with vector pHRL-null (Prom-
ega) for transfection e⁄ciency and indexing of luciferase activity. Cells
were transfected using E¡ectene0 optimized according to the manu-
facturer’s instructions. 24 h post-transfection, cells were pre-incubated
with the inhibitor or vehicle for 30 min. Cells were then incubated
under normoxic conditions or exposed to hypoxia for a further 24 h in
growth medium containing 2% fetal bovine serum (FBS). Alternately,
the NO donor S-nitrosoglutathione (GSNO) was added and cultures
incubated for 24 h in growth medium containing 2% FBS and 10 mM
HEPES. In experiments involving the PTEN expression plasmids, all
cell groups that received PTEN were also co-transfected with pCMV-
LacZ for control purposes. Dual luciferase output (Dual-Luciferase1
Reporter Assay System) was quanti¢ed with a luminometer and re-
sults expressed as an index of relative light units (RLU).
2.7. Statistical analysis
Mean values were calculated from data obtained from three or
more separate experiments. The signi¢cance was assessed by Student’s
t-test. Statistical signi¢cance was con¢rmed at a P value 6 0.01. A
minimum of three independent experiments was used to con¢rm ob-
servations.
3. Results and discussion
3.1. E¡ect of inhibitors of protein kinase on HIF-1 in hypoxic
HMEC-1 cells
HIF-1 is a phosphorylated protein [38^40]. To investigate
the role of protein phosphorylation in HIF-1K subunit stabi-
lization, HIF-1 DNA binding, and in the regulation of HIF-1
transcriptional activity in microvascular endothelium, we pre-
treated HMEC-1 with vehicle alone or with di¡erent inhibi-
tors for 30 min prior to hypoxic exposure. Nuclear extracts
were prepared as described in Section 2 after exposure of
HMEC-1 to hypoxia for 6 h and used for detection of HIF-
1K by Western blot analysis and for HIF-1 DNA binding
activity by EMSA with a labeled, double-stranded consensus
HIF-1 oligonucleotide. To determine HIF-1 transcriptional
activity, transfected HMEC-1 were exposed to hypoxia for
24 h and then harvested for DLR assay. As seen in Fig.
1A,B, hypoxia strongly induced stabilization of HIF-1K and
HIF-1 DNA binding activity. Pre-treatment with PD98059
(50 WM), an inhibitor of the ERK (extracellular signal-regu-
lated kinase) kinase pathway had no e¡ect on HIF-1K stabi-
lization or HIF-1 DNA binding by hypoxia. This result is in
agreement with the results from Salceda [40], Semenza [41],
and Michiels [42]. In contrast to results obtained in tumor cell
lines from Giaccia [43] and Semenza [15], the PI-3K/Akt in-
hibitor, LY294002 (25 WM), did not a¡ect the hypoxic sta-
bilization of HIF-1K or HIF-1 DNA binding activity in
HMEC-1. However, both PD98059 and LY294002 suppressed
hypoxia-induced transcriptional activity of HIF-1 (Fig. 1C).
This suggests that the PI-3K/Akt pathway and ERK signaling
pathways are involved only in the regulation of the transacti-
vation ability of hypoxia-induced HIF-1.
Pre-treatment with the tyrosine kinase inhibitors, genistein
(100 WM) or herbimycin A (2 WM), signi¢cantly blocked hyp-
oxia-induced stabilization of HIF-1K and HIF-1 DNA bind-
ing activity (Fig. 1A,B). This is in accordance to results from
Semenza [44], who used genistein to show the involvement of
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tyrosine phosphorylation in hypoxic induction of HIF-1K.
Accordingly, HIF-1-dependent transcriptional ability was se-
verely compromised (Fig. 1C).
The highly speci¢c inhibitor of protein kinase C (PKC),
Calphostin C (100 nM), repressed only the hypoxia-induced
transcriptional ability of HIF-1 without signi¢cantly a¡ecting
either the hypoxic stabilization of HIF-1K or HIF-1 DNA
binding activity in HMEC-1. While PKC has been implicated
in transmitting hypoxia-induced signals to HIF-1 [45], sup-
pression of hypoxia-induced HIF-1 transcriptional ability by
a PKC inhibitor has not yet been reported. Thus protein
phosphorylation events play an active role in hypoxia-induced
HIF-1 activation in HMEC-1.
3.2. E¡ect of inhibitors of protein kinases on HIF-1 in
HMEC-1 exposed to nitric oxide
Diverse nitric oxide donors as well as endogenously gener-
ated NO have recently been shown to induce HIF-1K stabili-
zation, HIF-1 DNA binding and transactivation under nor-
moxic conditions [18,20,22,46]. HIF-1K has been shown to
be extensively S-nitrosated [47]. A possible role for tyrosine
phosphorylation and involvement of the PI-3K/Akt pathway
in NO-dependent stabilization of HIF-1K and HIF-1-depen-
dent transactivation in proximal tubular LLC-PK1 cells has
been demonstrated [18,22]. However, the role of protein phos-
phorylation in NO-mediated HIF-1 DNA binding and trans-
activation under normoxic conditions in microvascular endo-
thelium remains unidenti¢ed. We therefore pre-treated
HMEC-1 with vehicle alone or with di¡erent inhibitors for
30 min prior to exposure to the NO donor, GSNO (500
WM) for 5 h. GSNO produced robust stabilization of HIF-
1K in HMEC-1 (Fig. 2A) as well as strong DNA binding
activity (Fig. 2B) and transcriptional activity (Fig. 2C). Sim-
ilar to the hypoxic response of HIF-1, the ERK pathway
inhibitor, PD98059 (50 WM), had no e¡ect on either HIF-1K
stabilization or HIF-1 DNA binding activity (Fig. 2A,B) by
NO. However, pre-treatment with PD98059 produced a sharp
decrease in HIF-1 transcriptional activity. This suggests that,
similar to hypoxia, the ERK pathway is involved in regulation
of HIF-1-dependent transcriptional activity by NO. Taken
together with data shown in Fig. 1, the ERK signaling path-
Fig. 1. E¡ect of inhibitors of protein kinase on HIF-1 in hypoxic
HMEC-1 cells. Con£uent HMEC-1 cells were exposed to vehicle
alone or to di¡erent inhibitors for 30 min prior to hypoxic exposure
for 6 h. Nuclear extracts were isolated and used for A: Western
blot analysis (20 Wg) for HIF-1K or B: EMSA analysis for HIF-1.
N, normoxia (21% O2); hypoxia (1% O2); V, vehicle; PD, PD98059
(50 WM); LY, LY294002 (25 WM); G, genistein (100 WM); H, herbi-
mycin A (2 WM); CC, Calphostin C (100 nM). C: HMEC-1 cultures
were transiently co-transfected with pHRE-luc and pHRL-null. 24 h
post-transfection, HMEC-1 cells were exposed to vehicle alone or to
di¡erent inhibitors for 30 min prior to hypoxic exposure for 24 h.
Dual luciferase output was quanti¢ed and the results expressed as
an index of relative light units (RLU) RS.E.M. of three indepen-
dent transfections (*, P6 0.005; #, P6 0.01).
Fig. 2. E¡ect of inhibitors of protein kinases on HIF-1 in HMEC-1
exposed to nitric oxide. Con£uent HMEC-1 cells were exposed to
vehicle alone or to di¡erent inhibitors for 30 min prior to exposure
to the NO donor, GSNO (500 WM), for 5 h. Nuclear extracts were
isolated and used for A: Western blot analysis (20 Wg) for HIF-1K
or B: EMSA analysis for HIF-1. M, media; nitric oxide, GSNO
(500 WM); V, vehicle; PD, PD98059 (50 WM); LY, LY294002 (25
WM); G, genistein (100 WM); H, herbimycin A (2 WM); CC, Cal-
phostin C (100 nM). C: HMEC-1 cultures were transiently co-trans-
fected with pHRE-luc and pHRL-null. 24 h post-transfection,
HMEC-1 cells were exposed to vehicle alone or to di¡erent inhibi-
tors for 30 min prior to exposure to GSNO (500 WM) for 5 h. Dual
luciferase output was quanti¢ed and the results expressed as an in-
dex of relative light units (RLU) RS.E.M. of three independent
transfections (*, P6 0.001; #, P6 0.005; %, P6 0.05).
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way appears to be involved in regulation of the transactiva-
tion ability of HIF-1 following exposure to both hypoxia and
NO.
Next we explored signal transmission involving PI-3K by
using the speci¢c PI-3K inhibitor LY294002. Unlike hypoxic
exposure, both HIF-1K stabilization and HIF-1 DNA bind-
ing, as well as HIF-1-mediated transactivation following ex-
posure to GSNO, were blocked by pre-treatment with
LY294002 (50 WM) (Fig. 2), implying an essential role of
the PI-3K pathway for NO-triggered HIF-1 activation. Thus
data from Figs. 1 and 2 suggest that PI-3K pathway involve-
ment of HIF-1-dependent gene expression is di¡erentially
regulated following exposure to hypoxia and NO.
Involvement of protein tyrosine phosphorylation was
studied by pre-treatment with genistein (100 WM) and herbi-
mycin A (2 WM). As seen in Fig. 2, both genistein and herbi-
mycin were e¡ective in blocking HIF-1K stabilization, HIF-1
DNA binding and transactivation following exposure to NO.
While Sandau et al. [22] showed that genistein blocked the
stabilization of NO-induced HIF-1K in LLC-PK1 cells, the
e¡ect of these inhibitors on NO-induced HIF-1 DNA binding
and transactivation is a novel ¢nding.
PKC has been implicated in transmitting hypoxia-induced
signals of HIF-1 and is reported to be upstream of PI-3K [45].
However, the involvement of PKC in transmitting NO-in-
duced signals to HIF-1 remains unknown. HMEC-1 cells
were pre-treated with the highly speci¢c inhibitor of protein
kinase C, Calphostin C (100 nM), prior to exposure to GSNO
(500 WM). As seen in Fig. 2, HIF-1K stabilization by GSNO
was moderately diminished in the presence of Calphostin C.
Accordingly, both HIF-1 DNA binding and transactivation
were moderately repressed, implying that PKC may be in-
volved in NO-mediated HIF-1K stabilization.
3.3. E¡ect of PTEN over-expression on HIF-1-dependent
transactivation in hypoxic and NO-exposed HMEC-1 cells
As demonstrated in Figs. 1 and 2, the PI-3K pathway is
di¡erentially involved in the regulation of HIF-1 following
exposure to hypoxia or NO. While data from Fig. 1 showed
that the PI-3K/Akt pathway is involved only in regulation of
the transactivation ability of hypoxia-induced HIF-1, data
from Fig. 2 suggest that PI-3K is required for HIF-1K stabi-
lization, HIF-1 DNA binding as wel as HIF-1-mediated trans-
activation following exposure to NO. We therefore used mo-
lecular tools to further examine the involvement of the PI-3K
pathway in HIF-1 transactivation in microvascular endothe-
lium and performed transient transfection assays using wild-
type and mutant over-expression vectors for PTEN. HMEC-1
cells were co-transfected with pHRE-luc, pHRL-null and ei-
ther the expression plasmids encoding wild-type PTEN
(PTEN), mutant PTEN de¢cient in lipid phosphatase activity,
PTEN(G129E) [34] or mutant PTEN de¢cient in both lipid
and protein phosphates activities, PTEN(C124S) [35]. 24 h
post-transfection, cells were exposed to hypoxia or to
GSNO for 24 h prior to harvest for DLR assay. As seen in
Fig. 3, both hypoxia and GSNO produced a robust increase
in pHRE-luc activity. Over-expression of PTEN decreased
NO-driven luciferase activity by 50% but had no e¡ect on
the hypoxia-induced luciferase activity. This suggests that
hypoxia-driven HIF-1 transactivation is PI-3K-independent
and is in agreement with reports by Arsham et al. [23] and
Alvarez-Tejado et al. [24]. This is in contrast to the data
shown in Fig. 1C, in which the PI-3K inhibitor, LY294002,
suppressed hypoxia-driven pHRE-luc activity. In this regard it
has recently been reported that LY294002 inhibits casein ki-
nase II at doses similar to those required to inhibit PI-3K [48]
and could account for the decrease in HIF-1 transactivation
seen in Fig. 1C. On the other hand, PI-3K appears to be
essential for NO-dependent HIF-1 transactivation.
Co-transfection with the lipid phosphatase mutant
PTEN(G129E) decreased NO-driven luciferase activity, sug-
gesting that the protein phosphatase activity of PTEN was
required for NO-driven HIF-1 activation. It is possible that
the decrease observed here arose due to lower e⁄ciencies of
transfection. However, this appears unlikely since the PTEN-
(C124S) mutant, which lacks both lipid and protein phospha-
tase activities, abrogated the suppression observed with the
wild-type PTEN. Taken together with the data presented in
Fig. 2, this suggests that the NO-dependent transactivation of
HIF-1 was dependent on both the protein phosphatase activ-
ity and lipid phosphatase activity of PTEN. While the lipid
phosphatase activity of PTEN has been extensively shown to
be involved in its tumor suppressor function, the role of its
protein phosphatase activity has remained largely unknown.
The protein phosphatase activity of PTEN has been shown to
be involved in the inhibition of cell migration and invasion by
targeting the focal adhesion kinase [49] and also in the sup-
pression of matrix metalloproteinase-2 gene expression in hu-
man glioma cells [50]. Our results show for the ¢rst time that
the protein phosphatase activity of PTEN may be involved in
the induction of HIF-1-dependent transactivation by NO.
3.4. Involvement of Akt in HIF-1 activation by hypoxic and
NO-exposed HMEC-1 cells
Akt kinase, also known as protein kinase B, is well recog-
nized as a downstream target of PI-3K. Therefore we exam-
ined the activation of Akt by hypoxia and NO in microvas-
cular endothelium. First we determined if Akt could be
phosphorylated by endogenous NO. Acetyl choline has been
demonstrated to rapidly activate endothelial constitutive nitric
oxide synthase (ecNOS) [51,52], whereas cytomix (IL-1L,
Fig. 3. E¡ect of PTEN over-expression on HIF-1-dependent trans-
activation in hypoxic and NO-exposed HMEC-1 cells. HMEC-1
cells were co-transfected with pHRE-luc, pHRL-null and either the
expression plasmids encoding wild-type PTEN (PTEN) or mutant
plasmids PTEN(G129E) or PTEN(C124S). 24 h post-transfection,
cells were exposed to hypoxia or to GSNO (500 WM) for 24 h prior
to harvest for DLR assay. Results expressed as an index of rela-
tive light units (RLU) RS.E.M. of three independent transfections
(*, P6 0.01).
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IFN-Q and TNF-K) activates inducible nitric oxide synthase
(iNOS) [53]. Therefore we exposed HMEC-1 cells to acetyl
choline (1 WM) for 10, 20, 30 and 60 min or cytomix (10
pg/ml each of IL-1L, IFN-Q and TNF-K) for 1, 2, 4, 6 and
24 h and examined the activation of Akt by Western blot
analysis. Since phosphorylation of Ser473 on Akt re£ects its
active form we used a phospho-speci¢c ser473Akt antibody in
Western blots to probe for Akt activation. As seen in Fig. 4A,
acetyl choline, which activates ecNOS, rapidly induced Akt
phosphorylation. Akt activation was observed after only a
10 min exposure to acetyl choline and then was followed by
a gradual decline in activated Akt. Cytomix, which activates
iNOS at the transcriptional level, also induced Akt phosphor-
ylation at 1 h. Levels of P-Akt gradually declined and reached
basal levels after 24 h exposure to cytomix. Parallel experi-
ments performed following transfection of HMEC-1 with
pHRE-luc resulted in increased HIF-1-driven luciferase activ-
ity following exposure to either acetyl choline or cytomix
(data not shown), suggesting that endogenous NO stimulates
HIF-1-dependent transcription in a PI-3K/Akt-dependent
manner. Next we examined the activation of Akt by hypoxia
and exogenous NO. HMEC-1 cells were pre-incubated with
LY294002 for 30 min prior to exposure to hypoxia (6 h) or
GSNO (500 WM, 5 h). As seen in Fig. 4B, exposure of
HMEC-1 to GSNO resulted in a more than two-fold increase
in Akt activation that could be suppressed by LY294002. Ex-
posure to hypoxia (Fig. 4C), however, failed to activate Akt,
suggesting that Akt activation may not be required for hy-
poxic induction of HIF-1. These results further support our
data in Fig. 3 that PI-3K is not involved in hypoxic activation
of HIF-1. Western blots were stripped and re-probed with an
Akt antibody that recognizes the unphosphorylated form of
Akt to ensure equal loading.
Thus, in this study we showed that HIF-1 is activated under
non-hypoxic conditions by NO. Protein phosphorylation
events are involved in HIF-1 activation, both during hypoxia
and NO exposure. Speci¢cally, the ERK and PKC signaling
pathways are involved in regulation of the transactivation
ability of HIF-1 following exposure to both hypoxia and
NO. The PI-3K pathway has di¡erential e¡ects on HIF-1
activation. The data presented here indicate that the PI-3K/
Akt pathway is not required for HIF-1K induction, nor does it
play an essential role in HIF-1 transactivation during hypox-
ia. In contradistinction, NO-dependent HIF-1K stabilization
and HIF-1 transactivation potential are regulated by PI-3K/
Akt. Since over-expression mut PTEN signi¢cantly decreased
HIF-1-dependent transactivation but did not abolish it com-
pletely, both the lipid phosphatase and protein phosphatase
activities of PTEN appear to be involved in regulation of
HIF-1K by NO. Future studies of the protein phosphatase
targets of PTEN would provide important information for
regulation of HIF-1 under conditions associated with massive
NO production such as in£ammation and ischemia-reperfu-
sion.
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